Literature DB >> 31408905

Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.

Jochen G Mainz1,2, Ruth Katharina Michl1, Natalie Beiersdorf1, Michael Lorenz1, Uwe Schneider3, Tanja Groten3, Anke Jaudszus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31408905     DOI： 10.1055/a-0973-8565

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN： 0300-8630            Impact factor:   1.349


× No keyword cloud information.
  4 in total

1.  Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.

Authors:  Raksha Jain; Amalia Magaret; Phuong T Vu; Jill M VanDalfsen; Ashley Keller; Alexandra Wilson; Melissa S Putman; Nicole Mayer-Hamblett; Charles R Esther; Jennifer L Taylor-Cousar
Journal:  BMJ Open Respir Res       Date:  2022-06

Review 2.  Challenges in the use of highly effective modulator treatment for cystic fibrosis.

Authors:  Kathleen J Ramos; Joseph M Pilewski; Jennifer L Taylor-Cousar
Journal:  J Cyst Fibros       Date:  2021-01-30       Impact factor: 5.482

Review 3.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.

Authors:  Renée V E Dagenais; Victoria C H Su; Bradley S Quon
Journal:  J Clin Med       Date:  2020-12-23       Impact factor: 4.241

Review 4.  Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era.

Authors:  Raksha Jain; Jennifer L Taylor-Cousar
Journal:  J Pers Med       Date:  2021-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.